Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.
2.

The impact of emerging safety and effectiveness evidence on the use of physician-administered drugs: the case of bevacizumab for breast cancer.

Conti RM, Dusetzina SB, Herbert AC, Berndt ER, Huskamp HA, Keating NL.

Med Care. 2013 Jul;51(7):622-7. doi: 10.1097/MLR.0b013e318290216f.

3.

Does managed care affect the diffusion of psychotropic medications?

Domino ME.

Health Econ. 2012 Apr;21(4):428-43. doi: 10.1002/hec.1723.

4.

Who are the new users of antipsychotic medications?

Domino ME, Swartz MS.

Psychiatr Serv. 2008 May;59(5):507-14. doi: 10.1176/ps.2008.59.5.507.

5.

Changes in how health plans provide behavioral health services.

Horgan CM, Garnick DW, Merrick EL, Hodgkin D.

J Behav Health Serv Res. 2009 Jan;36(1):11-24.

6.

Prescription drug use and expenditures among dually eligible beneficiaries.

Bagchi AD, Esposito D, Verdier JM.

Health Care Financ Rev. 2007 Summer;28(4):43-56.

7.

Medicaid's expenditures for newer pharmacotherapies for adults with disabilities.

Shireman TI, Hall JP, Rigler SK, Moore JM.

Health Care Financ Rev. 2007 Summer;28(4):31-41.

8.

Availability of addiction medications in private health plans.

Horgan CM, Reif S, Hodgkin D, Garnick DW, Merrick EL.

J Subst Abuse Treat. 2008 Mar;34(2):147-56.

9.
10.

Economic grand rounds: potential effects of the new medicare drug benefit on pricing for psychotropic medications.

Huskamp HA, Shinogle JA.

Psychiatr Serv. 2005 Sep;56(9):1056-8. No abstract available.

Supplemental Content

Support Center